Patents by Inventor Sergej Michailovic Kiprijanov

Sergej Michailovic Kiprijanov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170051067
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: November 11, 2016
    Publication date: February 23, 2017
    Applicant: Cancer Research Technology Limited
    Inventors: Urs Beat Hagemann, Remko Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Publication number: 20160244527
    Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: May 11, 2016
    Publication date: August 25, 2016
    Applicant: AFFITECH RESEARCH AS
    Inventors: Anita KAVLIE, Sergej Michailovic KIPRIJANOV
  • Publication number: 20150104831
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 16, 2015
    Applicant: AFFITECH RESEARCH AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Publication number: 20140369925
    Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: May 16, 2014
    Publication date: December 18, 2014
    Applicant: AFFITECH RESEARCH AS
    Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov
  • Patent number: 8748107
    Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 10, 2014
    Assignee: Affitech Research AS
    Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov
  • Patent number: 8637017
    Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 28, 2014
    Assignee: Affitech Research AS
    Inventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov
  • Publication number: 20120164161
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 28, 2012
    Applicant: AFFITECH RESEARCH AS
    Inventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
  • Publication number: 20110311449
    Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Application
    Filed: February 10, 2011
    Publication date: December 22, 2011
    Applicant: AFFITECH RESEARCH AS
    Inventors: Anita Kavlie, Sergej Michailovic Kiprijanov
  • Publication number: 20100310463
    Abstract: Disclosed are antibodies that bind to Epithelial Cell Adhesion Molecule (EpCAM) and display certain advantages over known antibodies which bind to EpCAM, for example, the antibodies of the invention show good affinity, good cross-reactivity profiles and excellent ADCC and CDCC activity. Antibodies comprising specific heavy and light chain CDRs are disclosed. The invention thus relates to these antibodies and all uses thereof, in particular in the treatment of cancer. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer. Advantageous immunoconjugate compositions and methods using the new anti-EpCAM antibodies are also provided.
    Type: Application
    Filed: June 9, 2010
    Publication date: December 9, 2010
    Applicant: AFFITECH RESEARCH AS
    Inventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus, Jenny Margareta Karlsson, Remko Albert Griep, Sergej Michailovic Kiprijanov